Welcome to our dedicated page for INmune Bio news (Ticker: $INMB), a resource for investors and traders seeking the latest updates and insights on INmune Bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect INmune Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of INmune Bio's position in the market.
INmune Bio Inc. will report its first quarter 2024 financial results and provide a corporate update on May 9. The clinical-stage immunology company is focused on developing treatments leveraging a patient's innate immune system to combat diseases. A conference call and webcast will be hosted at 4:30 PM ET on the same day.
INmune Bio Inc. provides an update on two patients from the Phase 1b Alzheimer’s Disease Trial who have been receiving XPro™ for over three years under the Australian compassionate use program. Both patients have shown stable cognitive function and a desire to continue treatment. The long-term administration of XPro™ has been safe and well-tolerated, according to primary care physicians.
INmune Bio Inc., a clinical-stage immunology company, has completed the first cohort and initiated the second cohort of a Phase 1/2 study of INKmune™ Natural Killer Cell Therapy for metastatic castration-resistant prostate cancer. The company is encouraged by the safety and efficacy of the therapy, with approval granted to proceed with the second dose level. Prof. Mark Lowdell Ph.D., CSO of INmune Bio, highlights the potential of INKmune to transform resting NK cells into cancer-killing cells, offering a promising therapy for prostate cancer patients.
